Free Trial

PepGen (PEPG) Projected to Post Earnings on Wednesday

PepGen logo with Medical background
Remove Ads

PepGen (NASDAQ:PEPG - Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

PepGen (NASDAQ:PEPG - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.13. On average, analysts expect PepGen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PepGen Stock Up 29.6 %

Shares of PEPG stock traded up $0.72 during trading hours on Friday, reaching $3.15. The company's stock had a trading volume of 8,938,895 shares, compared to its average volume of 4,157,341. PepGen has a fifty-two week low of $1.16 and a fifty-two week high of $19.30. The company has a market capitalization of $102.68 million, a price-to-earnings ratio of -1.06 and a beta of 1.53. The firm's 50 day simple moving average is $2.37 and its 200-day simple moving average is $5.69.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PEPG shares. Bank of America downgraded PepGen from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a report on Monday, December 16th. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of PepGen in a report on Monday, February 24th. Finally, Wedbush cut their price objective on PepGen from $19.00 to $12.00 and set an "outperform" rating on the stock in a report on Friday, November 8th.

Remove Ads

Get Our Latest Research Report on PepGen

PepGen Company Profile

(Get Free Report)

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

Recommended Stories

Earnings History for PepGen (NASDAQ:PEPG)

Should You Invest $1,000 in PepGen Right Now?

Before you consider PepGen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.

While PepGen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads